Search Results

AnaptysBio's lead IL-33 antibody clears midstage test in asthma.

Subjects: INTERLEUKIN-33; ASTHMA diagnosis; PEANUT allergyANAPTYSBIO Inc.

• Source: FierceBiotech. 9/24/2018, pN.PAG-N.PAG. 1p.

Record details

Highly and Adaptively Undersampling Pattern for Pulmonary Hyperpolarized 129Xe Dynamic MRI.

• Authors : Xiao, Sa¹ (AUTHOR); Deng, He¹ (AUTHOR); Duan, Caohui¹ (AUTHOR)

Subjects: INTERLEUKIN-33; OBSTRUCTIVE lung diseases; COMPRESSED sensing

• Source: IEEE Transactions on Medical Imaging. May2019, Vol. 38 Issue 5, p1240-1250. 11p.

Record details

AstraZeneca axes kidney disease program after seeing phase 2b data, dealing another blow to IL-33.

• Authors : Taylor, Nick Paul (AUTHOR)

Subjects: KIDNEY diseases; INTERLEUKIN-33; VISUAL perceptionASTRAZENECA PLC ASTRAZENECA PLC ASTRAZENECA PLC AZN

• Source: FierceBiotech. 2/8/2024, pN.PAG-N.PAG. 1p.

Record details

Lycoperoside H, a steroidal alkaloid saponin in tomato seeds, ameliorates atopic dermatitis‐like symptoms in IL‐33 transgenic mice.

• Authors : Takeda, Shogo¹ (AUTHOR); Miyasaka, Kenchi¹ (AUTHOR); Shimoda, Hiroshi¹ (AUTHOR)

Subjects: TOMATO seeds; STEROIDAL alkaloids; TRANSGENIC mice

• Source: Journal of Food Biochemistry. Sep2021, Vol. 45 Issue 9, p1-11. 11p.

Record details

Alleviating age-related cognitive decline by activating immune cells.

• Authors : Liu, Angus (AUTHOR)

Subjects: NEURODEGENERATION; MEDICAL research personnel; MEDICAL schoolsBROWN University

• Source: FierceBiotech. 2/5/2020, pN.PAG-N.PAG. 1p.

Record details

FDA Delays Decision for Dupixent in COPD.

Subjects: *PHARMACEUTICAL industry; THERAPEUTIC use of monoclonal antibodies; INVESTIGATIONAL drugsUNITED States. Food & Drug Administration

• Source: Formulary Watch. 5/31/2024, p1-1. 1p.

Record details

FDA Grants Priority Review to Dupixent in COPD.

Subjects: THERAPEUTIC use of monoclonal antibodies; DRUG approval; BIOLOGICAL productsUNITED States. Food & Drug Administration

• Source: Formulary Watch. 2/23/2024, p1-1. 1p.

Record details

Regeneron and Sanofi bag breakthrough status for PD-1 latecomer.

• Authors : Taylor, Phil

Subjects: PROGRAMMED cell death 1 receptors; CANCER treatment; SQUAMOUS cell carcinomaREGENERON Pharmaceuticals Inc. 194873139 REGENERON Pharmaceuticals Inc. REGENERON Pharmaceuticals Inc. 194873139 194873139 REGENERON Pharmaceuticals Inc. 194873139 REGN; SANOFI SA

• Source: FierceBiotech. 9/8/2017, p1-1. 1p.

Record details